Pediatric glioblastoma - unlike normal cells - are sensitive to the combination of vorinostat and olaparib and to its downstream effector - phosphorylated eIF2α
K. Eytan, Z. Versano, M. Leitner, S. Paglin, A. Toren, M. Yalon
This study identifies that pediatric glioblastoma cells are sensitive to combinations of vorinostat and PARP-1 inhibitors, and to inhibitors of phosphorylated eIF2 dephosphorylation, with potential therapeutic implications.
bioRxiv · Nov 25, 2020 · PreprintCancer Biology